- Home
- FLNC vs MLTX Comparison
FLNC vs MLTX Comparison
Compare FLNC & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLNC | MLTX |
|---|---|---|
| Founded | 2018 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 974.7M | 1.1B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FLNC | MLTX |
|---|---|---|
| Price | $16.54 | $16.80 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 11 |
| Target Price | $16.00 | ★ $29.73 |
| AVG Volume (30 Days) | ★ 3.9M | 1.0M |
| Earning Date | 05-04-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,262,830,000.00 | N/A |
| Revenue This Year | $51.09 | N/A |
| Revenue Next Year | $21.09 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.46 | $5.95 |
| 52 Week High | $33.51 | $62.75 |
Technical Indicators
Market Signals| Indicator | FLNC | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 45.33 |
| Support Level | $13.92 | $15.20 |
| Resistance Level | $22.12 | $19.03 |
| Average True Range (ATR) | 1.00 | 0.71 |
| MACD | 0.41 | -0.24 |
| Stochastic Oscillator | 62.80 | 13.86 |
Price Performance
Historical ComparisonAbout FLNC Fluence Energy Inc.
Fluence Energy Inc is enabling the global clean energy transition with market-leading energy storage products and services, and digital applications for renewables and storage. Geographically, it derives a majority of its revenue from the Americas.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.